The prevalence of Neurological diseases is rising, and available treatments for many of these conditions are either minimally effective or nonexistent. Neurological diseases are one of the primary therapeutic areas where we have chosen to focus our efforts.
Read moreJulius Clinical’s focused approach has created a track record of excellence that testifies to our cardio-metabolic and kidney disease trial capabilities. We have honed our scientific site networks, collaborations with leading experts, and operational resources to deliver steady streams of patients and high-quality data for clients.
Read moreUnrecognised pathogens and reemerging infectious diseases are an ongoing threat to human health in every corner of the world. We contribute to important research in this area by conducting pioneering infectious disease and vaccine trials, doing what we do best: optimizing protocols and executing streamlined trials that deliver high-quality data.
Read moreThe prevalence of Neurological diseases is rising, and available treatments for many of these conditions are either minimally effective or nonexistent. Neurological diseases are one of the primary therapeutic areas where we have chosen to focus our efforts.
Read moreJulius Clinical’s focused approach has created a track record of excellence that testifies to our cardio-metabolic and kidney disease trial capabilities. We have honed our scientific site networks, collaborations with leading experts, and operational resources to deliver steady streams of patients and high-quality data for clients.
Read moreUnrecognised pathogens and reemerging infectious diseases are an ongoing threat to human health in every corner of the world. We contribute to important research in this area by conducting pioneering infectious disease and vaccine trials, doing what we do best: optimizing protocols and executing streamlined trials that deliver high-quality data.
Read more
Julius Clinical are proud to announce the successful completion of recruitment for the PRImus-AD study, a clinical Phase II study which investigates the safety and efficacy of the drug candidate PRI-002 for the treatment of Alzheimer's Disease....
A paper published in Clinical Rheumatology from the research group of our Scientific Officer Manuel Castro Cabezas and Chief Scientific Officer Rick Grobbee indicates that patients with rheumatoid arthritis with high liver fibrosis scores are like...
Zeist, Netherlands, [February 25, 2025] – Julius Clinical, a science-driven global CRO specializing in Neurological, Cardio-Metabolic, Renal and Rare Diseases, is pleased to announce the establishment of Julius Clinical Poland, a new operational...
"*" indicates required fields
"*" indicates required fields
